Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000166583 | SCV000217385 | likely benign | Hereditary cancer-predisposing syndrome | 2014-11-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Invitae | RCV000200361 | SCV000253223 | likely benign | Neurofibromatosis, type 1 | 2023-12-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001562934 | SCV001785781 | likely benign | not provided | 2020-11-02 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000200361 | SCV002561205 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485033 | SCV002802355 | likely benign | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2022-01-01 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV003316055 | SCV004016437 | likely benign | Neurofibromatosis, familial spinal | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001562934 | SCV004033553 | likely benign | not provided | 2023-08-01 | criteria provided, single submitter | clinical testing | NF1: BP4, BP7 |